unon
Silver
- Joined
- Apr 25, 2025
- Posts
- 605
- Reputation
- 710
WHAT IS INFIGRATINIB
SIDE EFFECTS
BLOODWORK NEEDED
FIRST Thread
@crazyguy @Mitläufer @Orka thoughts
Infigratinib, a selective tyrosine kinase inhibitor (TKI), has shown promising results in treating achondroplasia by increasing height velocity in children theoretically could be used in purperty. Clinical studied demonstrated that children who received higher doses of the medication experienced significant improvements in their annualized height growth. The study also emphasized that beginning treatment early is crucial for achieving the greatest benefits in skeletal development, particularly in the growth of the skull and long bones.
NOW HOW DOES IT WORK
Infigratinib is a selective tyrosine kinase inhibitor (TKI) that targets fibroblast growth factor receptors (FGFRs), specifically FGFR1, FGFR2, and FGFR3
NOW HOW DOES IT WORK
Infigratinib is a selective tyrosine kinase inhibitor (TKI) that targets fibroblast growth factor receptors (FGFRs), specifically FGFR1, FGFR2, and FGFR3
- How Infigratinib Works: Infigratinib is designed to counteract this overactivity. It binds to a specific part of the FGFRs, called the ATP-binding pocket. By binding to this site, infigratinib effectively blocks the ability of the FGFRs to become "activated" (a process called phosphorylation) and transmit their downstream signals.
- The Result: By inhibiting the hyperactive FGFR3 pathway, infigratinib helps to restore the normal regulation of chondrocyte proliferation and differentiation. This allows for improved endochondral bone growth, which is what leads to the observed increases in height velocity and improvements in skeletal development.
Infigratinib can cause several side effects, with some of the most common ones affecting the skin, nails, and eyes. The severity and type of side effects can vary. The table below lists common side effects and their management.
| Side Effect | Description | Management |
| Nail Toxicity | Changes to fingernails and toenails, such as brittleness, breaking, or separation from the nail bed. | Keep nails clean and dry. Avoid tight-fitting shoes or activities that put pressure on the hands and feet. |
| Stomatitis/Mouth Sores | Inflammation and sores inside the mouth, on the tongue, or lips. | Practice good oral hygiene. Use a soft toothbrush and avoid alcohol-based mouthwashes. Rinsing the mouth with a baking soda or salt water solution can help. Avoid spicy or acidic foods. |
| Dry Eyes | A feeling of dryness, irritation, or grittiness in the eyes. | Use over-the-counter artificial tears or lubricating eye drops as recommended by a doctor. Regular eye exams may be needed to monitor for more serious vision changes. |
| Fatigue | A general feeling of weakness, tiredness, or lack of energy that is not relieved by rest. | Plan for rest periods throughout the day. Light exercise, like a short walk, can also help. |
| Alopecia (Hair Loss) | Thinning or loss of hair on the scalp and other parts of the body. | Use a mild shampoo and avoid harsh hair products or excessive heat from styling tools. |
| Palmar-Plantar Erythrodysesthesia Syndrome (Hand-Foot Syndrome) | Redness, swelling, pain, or blistering on the palms of the hands and soles of the feet. | Keep hands and feet clean and moisturized with an alcohol-free lotion. Avoid tight shoes and socks and take breaks from activities that put pressure on these areas. |
| Hyperphosphatemia | An increase in the level of phosphate in the blood, which can lead to soft tissue calcification. | This is a direct effect of how the drug works and requires close monitoring by a doctor. It may be managed with diet, phosphate binders, or by adjusting the drug dosage. |
Bloodwork to Monitor while on Infigratinib
IM NOT GOING TO TELL YOU THE RANGE YOUR BIO MARKERS SHOULD BE because im lazy asf
| Blood Test | Reason for Monitoring | Clinical Significance | |
| Serum Phosphate | Primary monitoring parameter. Infigratinib's mechanism of action directly affects phosphate levels. It can cause hyperphosphatemia (high phosphate), which is a common side effect and a marker of the drug's activity. | Elevated phosphate levels can lead to soft tissue calcification, which is the buildup of minerals in the body's tissues. This requires close management and may necessitate dose adjustments or the use of phosphate-lowering medication. | |
| Liver Function Tests (LFTs | To monitor for liver toxicity. | Infigratinib can cause increases in liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase. Elevated levels can signal liver injury, requiring a dose reduction or temporary halt of treatment. | |
| Renal Function Tests | To assess kidney function. | This includes monitoring creatinine and blood urea nitrogen (BUN) levels. The drug can affect kidney function, and regular checks are important to detect any changes and prevent kidney damage. | |
| Complete Blood Count (CBC) | This includes monitoring creatinine and blood urea nitrogen (BUN) levels. The drug can affect kidney function, and regular checks are important to detect any changes and prevent kidney damage. | Infigratinib can affect blood cell production, leading to anemia (low red blood cells), leukopenia (low white blood cells), and thrombocytopenia (low platelets). Monitoring hemoglobin, white blood cell count, and platelet count is crucial. | |
| Electrolytes | To monitor for imbalances. | Beyond phosphate, other electrolytes like calcium and potassium can be affected. Imbalances can lead to various symptoms, including muscle cramps, fatigue, or heart rhythm issues. | |
| Lipid Panel | To check for elevated fats in the blood. |
| |
IM NOT GOING TO TELL YOU THE RANGE YOUR BIO MARKERS SHOULD BE because im lazy asf
Studies found that the highest dose, 0.25 mg/kg daily, showed the most significant increase in annualized height velocity and was maintained over an extended period. This dose was also generally well-tolerated, with most side effects being mild or moderate.
It's important to note that the dosage for children with achondroplasia is different from the dosage used for other conditions, such as cholangiocarcinoma (a type of cancer), for which infigratinib is already approved. For those conditions, the adult dose is typically 125 mg once daily in a 21-day on, 7-day off cycle
It's important to note that the dosage for children with achondroplasia is different from the dosage used for other conditions, such as cholangiocarcinoma (a type of cancer), for which infigratinib is already approved. For those conditions, the adult dose is typically 125 mg once daily in a 21-day on, 7-day off cycle
FIRST Thread
@crazyguy @Mitläufer @Orka thoughts
Last edited:
